Clinical Trial Update: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

An update on a Phase 1b trial evaluating datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy, with or without carboplatin, for advanced or metas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Dato-DXd (datopotamab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced or Metastatic NSCLC | Phase 1 | Status: ACTIVE_NOT_RECRUITING